CRIS Current Research Information System

DI STEFANO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.724
AS - Asia 3.371
EU - Europa 2.746
AF - Africa 245
SA - Sud America 203
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.301
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.675
CN - Cina 1.090
SG - Singapore 980
IT - Italia 734
VN - Vietnam 595
GB - Regno Unito 553
DE - Germania 276
HK - Hong Kong 230
SE - Svezia 224
IN - India 183
BR - Brasile 158
UA - Ucraina 142
KR - Corea 127
CH - Svizzera 124
RU - Federazione Russa 123
FR - Francia 122
IE - Irlanda 118
TG - Togo 85
NL - Olanda 75
CI - Costa d'Avorio 60
JP - Giappone 53
FI - Finlandia 50
BG - Bulgaria 43
ZA - Sudafrica 41
EE - Estonia 36
CA - Canada 28
AT - Austria 27
JO - Giordania 25
NG - Nigeria 25
BE - Belgio 22
AR - Argentina 21
ID - Indonesia 20
SC - Seychelles 20
ES - Italia 19
MX - Messico 16
PL - Polonia 15
TR - Turchia 15
TW - Taiwan 15
HR - Croazia 10
AU - Australia 8
IQ - Iraq 8
GR - Grecia 7
IR - Iran 7
DK - Danimarca 6
EC - Ecuador 6
MA - Marocco 6
LT - Lituania 5
PY - Paraguay 5
BD - Bangladesh 4
LB - Libano 4
CL - Cile 3
CO - Colombia 3
DZ - Algeria 3
MD - Moldavia 3
PT - Portogallo 3
RO - Romania 3
SA - Arabia Saudita 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
UY - Uruguay 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BH - Bahrain 1
BZ - Belize 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
KE - Kenya 1
LY - Libia 1
MU - Mauritius 1
MW - Malawi 1
NC - Nuova Caledonia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
RS - Serbia 1
SI - Slovenia 1
SM - San Marino 1
SN - Senegal 1
Totale 10.301
Salva come PNG Salva come JPEG
Città #
Singapore 693
Ashburn 520
Southend 442
Fairfield 374
Chandler 323
Hefei 298
Bologna 263
Hong Kong 215
Woodbridge 202
Santa Clara 201
Wilmington 169
Seattle 162
Houston 160
Ho Chi Minh City 127
Beijing 124
Ann Arbor 122
Hanoi 120
Bern 116
Dublin 116
Seoul 113
Cambridge 103
Princeton 100
Dong Ket 94
Jacksonville 87
Lomé 85
Boardman 81
Dallas 65
New York 64
Abidjan 60
Los Angeles 55
Milan 54
Nanjing 46
Redmond 46
Tokyo 46
Sofia 43
Westminster 41
Padova 39
Bengaluru 37
Helsinki 32
Berlin 31
Buffalo 31
Shenyang 29
Turin 27
Abeokuta 24
Amman 24
Jinan 24
Genoa 22
San Diego 22
Frankfurt am Main 21
Falkenstein 20
Brussels 19
Guangzhou 19
Redondo Beach 19
Saint Petersburg 19
Shanghai 19
Tianjin 19
Amsterdam 18
Changsha 18
São Paulo 18
Düsseldorf 17
Hangzhou 17
Rome 16
Haiphong 15
Mülheim 15
Nanchang 15
Vienna 14
Falls Church 13
Jakarta 13
London 13
Mahé 13
Nuremberg 13
Quận Bình Thạnh 13
Redwood City 13
Wanchai 13
Zhengzhou 13
Chicago 12
Munich 12
Ninh Bình 12
Verona 12
Yubileyny 12
Cesenatico 11
Hebei 11
Lauterbourg 11
Montreal 11
Paris 11
Warsaw 11
Phoenix 10
Turku 10
Bremen 9
Des Moines 9
Jiaxing 9
Can Tho 8
Castel Maggiore 8
Forlì 8
Haikou 8
Lappeenranta 8
Nerviano 8
Phủ Lý 8
Poplar 8
Thái Nguyên 8
Totale 6.952
Salva come PNG Salva come JPEG
Nome #
A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer 319
Lactate-Induced HBEGF Shedding and EGFR Activation: Paving the Way to a New Anticancer Therapeutic Opportunity 279
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells 239
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib 238
Insights into the activity of ARN24089, a new RAD51-BRCA2 disruptor that inhibits homologous recombination and achieves synthetic lethality in pancreatic cancer 226
A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. 224
Lactate preserves genome integrity and extends proliferative potential in cancer cells 223
Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy. 208
Altered glycosylation profile of purified plasma ACT from Alzheimer's disease. 208
Liver targeted doxorubicin: effects on rat regenerating hepatocytes. 206
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. 195
Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. 186
The activation of lactate dehydrogenase induced by mTOR drives neoplastic change in breast epithelial cells 186
Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines. 184
Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. 184
Identification and subsequent development of RAD51-BRCA2 disruptors through a fragment-based approach 183
Uso di coniugati della doxorubicina con albumina lattosaminata 181
Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells 181
LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells 176
Galloflavin (CAS 568-80-9), a novel inhibitor of lactate dehydrogenase. 175
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer 173
A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentation grade. 173
Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes. 170
Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. 170
Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin 169
Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. 169
Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment 168
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors 167
Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. 166
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. 165
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug. 159
Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. 159
Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A 158
Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. 156
Lactate is a potential promoter of tamoxifen resistance in MCF7 cells 156
Procedura per la preparazione di coniugati della doxorubicina con l’albumina umana lattosaminata 146
The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially higher than that in liver and bone marrow. 145
Albumin-drug conjugates in the treatment of hepatic disorders. 145
Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulationin Burkitt lymphoma cells via NAD/NADH-dependent inhibition of sirtuin-1 144
Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. 144
Differential enantiomers activity of ARN24089 to achieve synthetic lethality in pancreatic cancer 141
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity 141
Preomic profile of BxPC-3 cells after treatment with BRC4 140
Metabolic activation triggered by cAMP in MCF-7 cells generates lethal vulnerability to combined oxamate/etomoxir 140
Peptides inhibiting the assembly of monomeric human l‐lactate dehydrogenase into catalytically active homotetramer decrease the synthesis of lactate in cultured cells 137
Elevated plasma levels of alpha-1-antichymotripsin in age-related cognitive decline and Alzheimer's disease; a poential therapeutci target. 136
The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination 135
Lactate Can Modulate the Antineoplastic Effects of Doxorubicin and Relieve the Drug's Oxidative Damage on Cardiomyocytes 132
Process for the preparation of doxorubicin conjugates with lactosaminated human albumin 130
Doxorubicin coupled to lactosaminated albumin: enhanced drug levels in rat hepatocarcinomas. 129
Allosteric transitions of rabbit skeletal muscle lactate dehydrogenase induced by pH-dependent dissociation of the tetrameric enzyme 122
Use of conjugates of doxorubicin with lactosaminated albumin. 117
Lactosaminated human albumin: a hepatotropic carrier of drugs. 114
Lactate Upregulates the Expression of DNA Repair Genes, Causing Intrinsic Resistance of Cancer Cells to Cisplatin 114
NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases 107
Human lactate dehydrogenase A undergoes allosteric transitions under pH conditions inducing the dissociation of the tetrameric enzyme 105
Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors 102
null 101
Proteomic profile of BxPC-3 cells after treatment with BRC4 97
Lactate dehydrogenase inhibition: Exploring possible applications beyond cancer treatment 91
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy 85
null 78
Inhibition of lactate dehydrogenase activity as an approach to cancer therapy 77
null 71
RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer 61
null 51
Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues 49
Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas 48
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in cancer treatment 37
Postnatal development of rat colon epithelial cells is associated with changes in the expression of the beta 1,4-N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen of alpha 2,6-sialyltransferase activity towards N-acetyl-lactosamine 36
Design and synthesis of RAD51-BRCA2 disruptors to inhibit homologous recombination and synergize with Olaparib as new anticancer drug discovery concept 32
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy 26
Totale 10.485
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021506 0 0 0 0 0 80 21 32 106 50 42 175
2021/2022986 110 19 76 84 74 45 42 73 39 66 190 168
2022/20231.365 111 219 50 154 115 89 40 51 207 38 71 220
2023/2024670 89 79 46 57 41 121 66 37 15 41 22 56
2024/20251.896 108 167 119 159 335 103 148 81 66 138 117 355
2025/20262.768 710 512 428 458 469 191 0 0 0 0 0 0
Totale 10.485